Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + motesanib
- Development stage
- Phase 1
- Lead developer
- Amgen
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Docetaxel + motesanib is a combination therapy consisting of docetaxel, a chemotherapy medication that acts as a microtubule inhibitor, and motesanib, an investigational agent. This combination has been studied in phase 1b clinical trials for metastatic breast cancer. The maximum tolerated dose was established as motesanib 125 mg once daily when combined with docetaxel 100 mg/m² administered every 21 days. The combination showed an objective response rate of 56% among patients with measurable disease at baseline.
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel + motesanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + motesanib.